Michel Detheux - Mar 9, 2023 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Chief Executive Officer
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Stock symbol
ITOS
Transactions as of
Mar 9, 2023
Transactions value $
$0
Form type
4
Date filed
3/10/2023, 06:51 PM
Previous filing
Mar 10, 2023
Next filing
Dec 7, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITOS Stock Option (Right to Buy) Award $0 +346K $0.00 346K Mar 9, 2023 Common Stock 346K $16.66 Direct F1
transaction ITOS Stock Option (Right to Buy) Gift $0 -255K -73.7% $0.00 91K Mar 9, 2023 Common Stock 255K $16.66 Direct F1, F2
transaction ITOS Stock Option (Right to Buy) Gift $0 +255K $0.00 255K Mar 9, 2023 Common Stock 255K $16.66 By MG3A F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option shall vest over four years, with 25% vesting on March 9, 2024 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer.
F2 The reporting person transferred these stock options to MG3A, a Belgian partnership of which the reporting person is the manager and the reporting person's spouse is the successor manager.